Avelumab inducing hypothyroidism and hypoadrenalism

dc.contributor.authorAziz, Kashif
dc.contributor.authorShahbaz, Amir
dc.contributor.authorUmair, Muhammad
dc.contributor.authorSachmechi, Isaac
dc.date.accessioned2018-11-12T15:29:50Z
dc.date.available2018-11-12T15:29:50Z
dc.date.issued2018-06-06
dc.description.abstractAvelumab is an anti-PD-L1 (programmed death-ligand 1) immune checkpoint inhibitor (ICIs) and the monoclonal antibody that constitutes a major development in the immunotherapy of cancer. In 2017, The European Medicine Agency (EMA) approved it as an orphan drug for treatment of gastric cancer. Avelumab has recently been approved in the United States, Europe and Japan for treatment of metastatic Merkel cell carcinoma (MCC). Avelumab inhibits the interaction of Programmed cell death protein 1 (PD-1) on immune cells with PD-L1 on tumor cells, thus banishing immunosuppressive signals and leading to enhanced immune cell activation. Here we are revealing a case of the patient with metastatic gastric cancer receiving avelumab with the development of undesirable endocrinopathies during the course of treatment. We suggested that patients receiving avelumab immunotherapy should be monitored for signs and symptoms of thyroiditis, hypothyroidism and adrenal insufficiency, which may require immediate attention and supportive treatment by immunosuppression and respective hormone replacement.en
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/37667
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-19662
dc.language.isoen
dc.relation.ispartofseriesEXCLI Journal;Vol. 17 2018
dc.subjectavelumaben
dc.subjecthypothyroidismen
dc.subjecthypoadrenalismen
dc.subjectendocrinopathiesen
dc.subjectImmune Check Point Inhibitorsen
dc.subjectPd- L1en
dc.subject.ddc610
dc.titleAvelumab inducing hypothyroidism and hypoadrenalismen
dc.title.alternativea case report and review of literatureen
dc.typeText
dc.type.publicationtypearticle
dcterms.accessRightsopen access
eldorado.dnb.zdberstkatid2132560-1
eldorado.secondarypublicationtrue

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Aziz_06062018_proof.pdf
Size:
74.28 KB
Format:
Adobe Portable Document Format
Description:
DNB
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.85 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections